Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Nandakumar Narayanan
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07288450CT.gov Terazosin And Metabolic Engagement in Parkinson's Disease | — | Not Yet Recruiting | — | — | — |
NCT07464028CT.gov Terazosin And Metabolic Energetics in Parkinson's Disease | — | Not Yet Recruiting | — | — | — |
NCT07207057CT.gov Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial | — | Recruiting | — | — | — |
NCT05855577CT.gov Motor Function Efficacy of Pharmacological Treatments Targeting Energy Metabolism, in Parkinson's Patients | — | Unknown | — | — | — |
NCT05109364CT.gov Terazosin and Parkinson's Disease Extension Study | — | Active Not Recruiting | — | — | — |
NCT04386317CT.gov Terazosin Effect on Cardiac Changes in Early Parkinson's Disease | — | Active Not Recruiting | — | — | — |
NCT03905811CT.gov A Pilot Study of Terazosin for Parkinson's Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Parkinson Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Terazosin (this asset) | Nandakumar Narayanan | Approved | BB · 68 |
| Safinamide | Zambon SpA | P4 | A |
| Cvt-301 | Acorda Therapeutics | P3 | A |
| Istradefylline | Georgetown University | P4 | BBB |
| Rasagiline | Guangzhou Henovcom Bioscience Co. Ltd. | P4 | BBB |
| Pardoprunox | Abbott Products | P3 | BBB |
| Opicapone | Bial - Portela C S.A. | P4 | BBB |
| Ropinirole | Titan Pharmaceuticals | P4 | BBB |
| Carbidopa | Tanta University | P4 | BBB |
+42 more in the Parkinson Disease cohort
Other indications for Terazosin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Disease | — | P4 | BB · 65 |
| REM Sleep Behavior Disorder | — | P2 | CCC · 53 |
| Lewy Body Dementia | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Terazosin in Parkinson Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/terazosin-parkinson-disease-59152
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →